On Monday, the US Food and Drug Administration granted approval to a keenly-watched Alzheimer’s drug, aducanumab, developed by the drugmaker Biogen. The decision to approve the drug, which was once abandoned as a failure, has been the subject of debate within the scientific and regulatory community for months. Aducanumab, which will be marketed as Aduhelm, […]...